Patents Represented by Attorney, Agent or Law Firm Robert P. Blackburn
  • Patent number: 5977323
    Abstract: Two novel cytokines which are involved in an inflammatory response (inflammatory cytokines) are disclosed. The inflammatory cytokines have been isolated from activated peripheral blood, preferably monocytes adhered to plastic; or peripheral blood leukocytes induced with calcium ionophore and mezerin. The two cytokines are Gro .beta. and .gamma., and their cDNA and amino acid sequences are disclosed. The expression of the genes in various cells is presented. Assay and diagnostic utilities using the cytokines; recombinant materials and procedures; purification procedures; and monoclonal antibodies to the cytokines are also shown.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 2, 1999
    Assignees: Chiron Corporation, University of North Carolina at Chapel Hill
    Inventors: John Stephen Haskill, Peter Ralph, Danute E. Nitecki, George Martin
  • Patent number: 5968775
    Abstract: The present invention is directed to extracorporeal cell systems infected with hepatitis C virus (HCV). The present invention also relates to products of such cell systems and their use as vaccines and in immunoassays. Methods whereby HCV-infected extracorporeal cell systems are constructed are included, and various immunoassays to detect HCV antibodies are also presented. The HCV-infected cell systems can be used to screen putative antiviral agents.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: October 19, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Kathelyn S. Steimer, Amy J. Weiner
  • Patent number: 5965695
    Abstract: Peptoids are provided which are polymers comprised of monomer units wherein the monomer units include least some substitute amino acids and may include conventional amino acids. The peptoids can be synthesized in large numbers so as to provide libraries of peptoids which can be screened in order to isolate peptoids of desired biological activity. Although the peptoids may include amino acids, they preferably include only substituted amino acids and are designed in a manner so as to have a particular biological activity. Certain peptoids are designed to mimic as closely as possible the activity of known proteins. Other peptoids are designed so as to have greater or lesser activity than known proteins and may be designed so as to block known receptor sites and/or elicit a desired immunogenic response and thereby act as vaccines. In that the peptoids are comprised of substitute amino acids they can be designed to have structures which natural proteins cannot conform to.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: October 12, 1999
    Assignee: Chiron Corporation
    Inventors: Reyna J. Simon, Paul A. Bartlett, Daniel V. Santi
  • Patent number: 5965140
    Abstract: Novel immunogenic compositions are provided involving viral particles composed at least in part of hybrid proteins of at least a portion of a particle forming protein and one or more polypeptides having at least one epitope of interest. Nucleic acid sequences are employed coding for the hybrid protein which are introduced into a host cell for expression, either by themselves or in combination with other DNA sequences coding for particle forming proteins. Expression of the DNA sequences results in formation of particles which may be isolated and used as immunogens for production of antibodies for diagnostics purposes, passive immunization, vaccination, or other uses.Saccharomyces carlsbergensis, 2150-2-3 (pDC103), was deposited on Sep. 7, 1984, at the ATCC and given ATCC Accession No. 20726. Also, Saccharomyces cerevisiae PO17 (pCl/l-MCS29) was deposited at the ATCC on Sep. 5, 1985, and given ATCC Accession No. 20770.
    Type: Grant
    Filed: August 10, 1998
    Date of Patent: October 12, 1999
    Assignee: Chiron Corporation
    Inventors: Pablo D. T. Valenzuela, George Kuo, Philip J. Barr
  • Patent number: 5959092
    Abstract: Two new isolates of the Hepatitis C virus (HCV), J1 and J7, are disclosed. These new isolates comprise nucleotide and amino acid sequences which are distinct from the prototype HCV isolate, HCV1. Thus, J1 and J7 provide new polynucleotides and polypeptides for use, inter alia, in diagnostics, recombinant protein production and vaccine development.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: September 28, 1999
    Assignees: Chiron Corporation, The Director General of the National Institute of Health of Japan
    Inventors: Tatsuo Miyamura, Izumi Saito
  • Patent number: 5959095
    Abstract: New methods are provided for the amplification of a midivariant DNA containing an inserted target specific nucleic acid sequence(s) to enable detection of the presence of a target nucleic acid sequence in a test sample. One method employs midivariant DNA as a template for the synthesis of RNA catalyzed by QB replicase. Two midivariant DNA/probe conjugates including a nonreplicable portion of midivariant DNA and a target specific nucleic acid sequence (probe) are described. An amplification method including the steps of hybridization and ligation of the midivariant DNA/probe conjugates followed by replication of the DNA template has enabled detection of less than 200 template molecules. In a modified amplification method one of the midivariant DNA/probe conjugates further includes a RNA polymerase promoter sequence to enable transcription of the midivariant DNA template into RNA. The sequential ligation-transcription-replication method enables the detection of a single template molecule.
    Type: Grant
    Filed: December 9, 1994
    Date of Patent: September 28, 1999
    Assignee: Chiron Diagnostics Corporation
    Inventors: Richard A. Martinelli, Jeffrey J. Donahue, John T. Unger
  • Patent number: 5942220
    Abstract: Described herein are compositions that have prophylactic or therapeutic applications for disease resulting from the production of cytokines, and preferably the cytokine IL-6, wherein the compositions consist of activin like molecules.
    Type: Grant
    Filed: March 16, 1990
    Date of Patent: August 24, 1999
    Assignee: Chiron Corporation
    Inventors: Mary Kim Warren, Robert Drummund, Leah B. Conroy
  • Patent number: 5932219
    Abstract: The entire genome of the hepatitis D virus has been shown to be a circular single-stranded RNA of 1679 bases. Several open reading frames in both the genomic and complementary strands indicate possible protein products. The products encoded in one open reading frame, ORF5, are identified as viral polypeptides p24.sup..delta. and p27.sup..delta., of which the nuclear .delta. antigens in HDV infected liver is comprised. These products, as well as others encoded in ORFs 1, 2, 6, and 7 are produced in recombinant expression systems. The ORF5 products, in particular, are useful for HDV diagnosis and vaccines.
    Type: Grant
    Filed: May 25, 1995
    Date of Patent: August 3, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Kang-Sheng Wang, Qui-Lim Choo, Amy Joan Weiner, Lacy Rasco Overby
  • Patent number: 5932537
    Abstract: Medicaments and methods of using the same are disclosed for treating or preventing diseases resulting from undesirable cell adhesion of IL-1 receptor positive cells to biological materials, particular to endothelial cells, or autoimmune related diseases, preferably graft versus host disease, or IL-1 dependent cancers.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: August 3, 1999
    Assignee: Chiron Corporation
    Inventors: John S. Haskill, Peter Ralph, Joanna Mizen Watson
  • Patent number: 5932467
    Abstract: Cells producing recombinant retroviral particles are provided. The cells contain a first vector having a coding region encoding retroviral LTRs and a packaging signal under the control of an expression control system, a tRNA binding site located upstream from the packaging signal and origin of second strand DNA synthesis located downstream from the packaging signal. The cells also contain a second vector having a coding region encoding retroviral capsid proteins gag and pol under the control of an expression control system and a third vector having a coding region encoding a simian type D retrovirus envelope glycoprotein under the control of an expression control system.
    Type: Grant
    Filed: October 3, 1996
    Date of Patent: August 3, 1999
    Assignee: Chiron Corporation
    Inventors: Mohammad Ayub Khan, Robert O. Ralston, John E. Murphy
  • Patent number: 5925516
    Abstract: Medicaments, and methods of identifying the same, are described that are useful for treating papillomavirus diseases that have the characteristics of preventing, interfering with, or reversing the binding of the appropriate papillomavirus proteins E1 or E2 to a nucleotide sequence homologous to a nucleotide sequence present in the papillomavirus genome, or of the formation of a complex consisting of papillomavirus proteins E1 and E2, or the binding of the complex to the nucleotide sequence.
    Type: Grant
    Filed: April 27, 1995
    Date of Patent: July 20, 1999
    Assignees: Chiron Corporation, University of California
    Inventors: Michael R. Botchan, Robin Clark, Ian J. Mohr, Shaw Sun
  • Patent number: 5922857
    Abstract: Embodiments of the present invention feature methods and compositions for controlling the translation of viral peptides and proteins from viral nucleic acid, with particular applications to pestiviras and HCV. The methods and compositions feature control elements of the 5'UT region of the viral genome.
    Type: Grant
    Filed: May 12, 1995
    Date of Patent: July 13, 1999
    Assignee: Chiron Corporation
    Inventors: Jang H. Han, Richard R. Spaete, Byoung J. Yoo, Byung S. Suh, Mark J. Selby, Michael Houghton
  • Patent number: 5897758
    Abstract: An improvement to the coated wire electrode has been accomplished via inclusion of a fortiophore into a sensor device. Sensor devices of the present invention include: an internal reference element; a membrane; and a fortiophore. Fortiophores are neutral charge carriers, which complex reversibly a corresponding ion of the conductive material used as the internal reference element. The fortiophore provides an electrochemically defined and reproducible solid internal contact between the membrane and the internal reference element. This solid internal contact, for example, in ion selective sensors, provides more reproducible potential offsets and better precision, and faster wet up. The fortiophores can be utilized in other electrochemical devices.
    Type: Grant
    Filed: August 1, 1997
    Date of Patent: April 27, 1999
    Assignee: Chiron Diagnostics Corporation
    Inventors: John Musacchio, Urs Oesch
  • Patent number: 5891742
    Abstract: Compounds are quickly selected from a combinatorial library by contacting the library with a target (e.g., receptor), separating non-binding compounds from compound-target complexes, and analyzing the complexes or eluted compound by mass spectroscopy. SAR information is obtained by performing this selection at two or more different ratios of compound to target.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: April 6, 1999
    Assignee: Chiron Corporation
    Inventors: Gavin D. Dollinger, Verena D. Huebner, Surinder Kaur
  • Patent number: 5888814
    Abstract: A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: March 30, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl F. Perez
  • Patent number: 5888502
    Abstract: Recombinant retroviruses carrying a vector construct capable of preventing, inhibiting, stabilizing or reversing infectious, cancerous or auto-immune diseases are disclosed. More specifically, the recombinant retroviruses of the present invention are useful for (a) stimulating a specific immune response to an antigen or a pathogenic antigen; (b) inhibiting a function of a pathogenic agent, such as a virus; and (c) inhibiting the interaction of an agent with a host cell receptor. In addition, eucaryotic cells infected with, and pharmaceutical compositions containing such a recombinant retrovirus are disclosed. Various methods for producing recombinant retroviruses having unique characteristics, and methods for producing transgenic packaging animals or insects are also disclosed.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 30, 1999
    Inventors: Harry E. Guber, Douglas J. Jolly, James G. Respess, Paul K. Laikind
  • Patent number: 5889156
    Abstract: A virion expression system for a desired protein packaged in an envelope derived from a retrovirus useful in administering proteins which cross cell membranes in order to serve their function. Preferred virions are those that carry an RNA sequence that encodes cytokines or lymphokines, and includes IL-2, multiple drug resistance protein, and TNF.
    Type: Grant
    Filed: May 24, 1995
    Date of Patent: March 30, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Kriegler, Carl F. Perez
  • Patent number: 5888835
    Abstract: Method and apparatus for enabling resuspension wash and magnetic localization of sample components bound to particles with magnetic properties in reaction vessels during separation and wash for enhanced chemiluminescent signal generation in biomedical assays. The assays involve moving reaction vessels past magnetic arrays that partially localized the particles prior to passing a gap where washing occurs, with or without resuspension, after separating out the unbound components and liquid. The band of particles is further localized by a focusing magnet at the end of the array prior to dosing the vessel with acid for chemiluminescent purposes. A block of soft magnetic material is employed in place of a magnet in the gap to minimize magnetic strength at the gap. Trimmed magnets adjacent the gap cause left, then right, particle shifting that localizes the magnetizable particles. The gap enables improved resuspension by wash, whereas the localized particles enable more efficient resuspension by reagent.
    Type: Grant
    Filed: May 10, 1996
    Date of Patent: March 30, 1999
    Assignee: Chiron Diagnostics Corporation
    Inventors: Steven E. Bushnell, Tina K. Garyantes, Michael L. Malek, Howard J. Kirchick
  • Patent number: 5885784
    Abstract: Materials and compositions for making triglyceride controls, calibrators and standards are described. The materials are mono- and di- and tri- glycerides of medium length fatty acids mixed into compositions of human serum or other protein solutions to form stable, miscible solutions suitable for use as controls, calibrators and standards in clinical chemistry for measurement and quality control in assays for triglycerides. The materials described have been used as vehicles for oil-soluble, water-insoluble pharmaceuticals and as facial emollient oils for cosmetics, and as such are safe, functional, stable, rancid-resistant and very inexpensive compared with pure materials synthesized or described previously.
    Type: Grant
    Filed: January 11, 1996
    Date of Patent: March 23, 1999
    Assignee: Bio-Rad Laboratories, Inc.
    Inventors: Thomas H. Duffy, Carter J. Grandjean, Roy F. Schall, Jr.
  • Patent number: 5885799
    Abstract: The protease necessary for polyprotein processing in Hepatitis C virus is identified, cloned, and expressed. Proteases, truncated protease, and altered proteases are disclosed which are useful for cleavage of specific polypeptides, and for assay and design of antiviral agents specific for HCV.
    Type: Grant
    Filed: September 6, 1996
    Date of Patent: March 23, 1999
    Assignee: Chiron Corporation
    Inventors: Michael Houghton, Qui-Lim Choo, George Kuo